achievable
Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Takeda Pharmaceutical Company
10-01-2017, 01:17 PM.
Post: #1
Takeda Pharmaceutical Company
Start a new thread for Takeda.

Takeda to Acquire ARIAD Pharmaceuticals, Inc.
Highlights :
* Highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors and reinforcing existing strength in hematology
* Accretive to Takeda’s Underlying Core Earnings by FY2018 and generates immediate and long-term revenue growth
* Attractive value drivers include two very innovative precision medicines, Iclusig (ponatinib) and brigatinib, an exciting early stage pipeline and cost synergies
* Takeda will leverage ARIAD’s research and development capabilities and platform
* Takeda retains financial flexibility with no impact on dividend policy

More details in http://infopub.sgx.com/FileOpen/E-PressR...eID=435316

- Iclusig is a globally commercialized product with continued strong sales growth potential
- Brigatinib approval in the U.S. is expected in the first half of 2017, with peak sales potential over $1 billion and the potential to be the best-in-class ALK inhibitor
Specuvestor: Asset - Business - Structure.

http://www.valuebuddies.com
Website Find Reply
10-01-2017, 02:13 PM.
Post: #2
RE: Takeda Pharmaceutical Company
(10-01-2017, 01:17 PM)cyclone Wrote: Start a new thread for Takeda.

Takeda to Acquire ARIAD Pharmaceuticals, Inc.
Highlights :
* Highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors and reinforcing existing strength in hematology
* Accretive to Takeda’s Underlying Core Earnings by FY2018 and generates immediate and long-term revenue growth
* Attractive value drivers include two very innovative precision medicines, Iclusig (ponatinib) and brigatinib, an exciting early stage pipeline and cost synergies
* Takeda will leverage ARIAD’s research and development capabilities and platform
* Takeda retains financial flexibility with no impact on dividend policy

More details in http://infopub.sgx.com/FileOpen/E-PressR...eID=435316

- Iclusig is a globally commercialized product with continued strong sales growth potential
- Brigatinib approval in the U.S. is expected in the first half of 2017, with peak sales potential over $1 billion and the potential to be the best-in-class ALK inhibitor

After failing to buy Salix from Valeant, they're feeling the heat to buy SOMETHING to cover the loss of earnings from loss of exclusivity from their branded drugs.

Find Reply
08-05-2018, 06:14 PM.
Post: #3
RE: Takeda Pharmaceutical Company
Japan's Takeda clinches $62 billion deal to buy drugmaker Shire

Paul Sandle, Ben Hirschler, Sam Nussey
May 8, 2018

LONDON/TOKYO (Reuters) - Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($61.50 billion) on Tuesday after the Japanese company raised the amount of cash in its offer to secure a recommendation.

The deal — assuming it wins the backing of shareholders — will be the largest overseas acquisition by a Japanese company and propel Takeda, led by Frenchman Christophe Weber, into the top ranks of global drugmakers.

The tie-up is one of the largest ever in the pharmaceuticals sector, crowning a hectic few months of deal-making as big drugmakers look to improve their pipelines by bringing in promising medicines developed by younger companies.

The enlarged group will be a leader in treatments in gastroenterology, neuroscience, oncology, rare diseases and blood-derived therapies, used for serious conditions such as hemophilia.

The agreement came on the last day for Takeda to make a firm bid. Shire had rejected four previous offers, due to price concerns and the fact that the Japanese company is proposing to pay for much of the acquisition in stock.

The final deal is approximately 46 percent cash and 54 percent stock, leaving Shire shareholders owning around half of the combined group.

Shire investors will receive $30.33 in cash and either 0.839 new Takeda shares or 1.678 Takeda American depositary shares for each share, the companies said, valuing the offer at 48.17 pounds a share based on the latest price and exchange rate.

More details in https://www.reuters.com/article/us-shire...SKBN1I90IC
Specuvestor: Asset - Business - Structure.

http://www.valuebuddies.com
Website Find Reply


Forum Jump:


Users browsing this thread: 1 Guest(s)
Valuebuddies.com | Return to Top | Lite (Archive) Mode | RSS Syndication | CONTACT US: nas......@valuebuddies.com | | Share Buy-Back | Disclosure of Interest